Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis
Copyright © 2024. Published by Elsevier Inc..
BACKGROUND: Imaging with late gadolinium enhancement (LGE) magnetic resonance (MR) and 18F-fluorodeoxyglucose (18F-FDG) PET allows complementary assessment of myocardial injury and disease activity and has shown promise for improved characterization of active cardiac sarcoidosis (CS) based on the combined positive imaging outcome, MR(+)PET(+).
OBJECTIVES: This study aims to evaluate qualitative and quantitative assessments of hybrid MR/PET imaging in CS and to evaluate its association with cardiac-related outcomes.
METHODS: A total of 148 patients with suspected CS underwent hybrid MR/PET imaging. Patients were classified based on the presence/absence of LGE (MR+/MR-), presence/absence of 18F-FDG (PET+/PET-), and pattern of 18F-FDG uptake (focal/diffuse) into the following categories: MR(+)PET(+)FOCAL, MR(+)PET(+)DIFFUSE, MR(+)PET(-), MR(-)PET(+)FOCAL, MR(-)PET(+)DIFFUSE, MR(-)PET(-). Further analysis classified MR positivity based on %LGE exceeding 5.7% as MR(+/-)5.7%. Quantitative values of standard uptake value, target-to-background ratio, target-to-normal-myocardium ratio (TNMRmax), and T2 were measured. The primary clinical endpoint was met by the occurrence of cardiac arrest, ventricular tachycardia, or secondary prevention implantable cardioverter-defibrillator (ICD) before the end of the study. The secondary endpoint was met by any of the primary endpoint criteria plus heart failure or heart block. MR/PET imaging results were compared between those meeting or not meeting the clinical endpoints.
RESULTS: Patients designated MR(+)5.7%PET(+)FOCAL had increased odds of meeting the primary clinical endpoint compared to those with all other imaging classifications (unadjusted OR: 9.2 [95% CI: 3.0-28.7]; P = 0.0001), which was higher than the odds based on MR or PET alone. TNMRmax achieved an area under the receiver-operating characteristic curve of 0.90 for separating MR(+)PET(+)FOCAL from non-MR(+)PET(+)FOCAL, and 0.77 for separating those reaching the clinical endpoint from those not reaching the clinical endpoint.
CONCLUSIONS: Hybrid MR/PET image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had modest sensitivity and specificity for quantifying the imaging-based classification MR(+)PET(+)FOCAL and was associated with outcomes. Use of combined MR and PET image-based classification may have use in prognostication and treatment management in CS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
JACC. Cardiovascular imaging - 17(2024), 4 vom: 01. Apr., Seite 411-424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trivieri, Maria Giovanna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcmg.2023.11.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367895013 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367895013 | ||
| 003 | DE-627 | ||
| 005 | 20240405233458.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcmg.2023.11.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM367895013 | ||
| 035 | |a (NLM)38300202 | ||
| 035 | |a (PII)S1936-878X(23)00529-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trivieri, Maria Giovanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Imaging with late gadolinium enhancement (LGE) magnetic resonance (MR) and 18F-fluorodeoxyglucose (18F-FDG) PET allows complementary assessment of myocardial injury and disease activity and has shown promise for improved characterization of active cardiac sarcoidosis (CS) based on the combined positive imaging outcome, MR(+)PET(+) | ||
| 520 | |a OBJECTIVES: This study aims to evaluate qualitative and quantitative assessments of hybrid MR/PET imaging in CS and to evaluate its association with cardiac-related outcomes | ||
| 520 | |a METHODS: A total of 148 patients with suspected CS underwent hybrid MR/PET imaging. Patients were classified based on the presence/absence of LGE (MR+/MR-), presence/absence of 18F-FDG (PET+/PET-), and pattern of 18F-FDG uptake (focal/diffuse) into the following categories: MR(+)PET(+)FOCAL, MR(+)PET(+)DIFFUSE, MR(+)PET(-), MR(-)PET(+)FOCAL, MR(-)PET(+)DIFFUSE, MR(-)PET(-). Further analysis classified MR positivity based on %LGE exceeding 5.7% as MR(+/-)5.7%. Quantitative values of standard uptake value, target-to-background ratio, target-to-normal-myocardium ratio (TNMRmax), and T2 were measured. The primary clinical endpoint was met by the occurrence of cardiac arrest, ventricular tachycardia, or secondary prevention implantable cardioverter-defibrillator (ICD) before the end of the study. The secondary endpoint was met by any of the primary endpoint criteria plus heart failure or heart block. MR/PET imaging results were compared between those meeting or not meeting the clinical endpoints | ||
| 520 | |a RESULTS: Patients designated MR(+)5.7%PET(+)FOCAL had increased odds of meeting the primary clinical endpoint compared to those with all other imaging classifications (unadjusted OR: 9.2 [95% CI: 3.0-28.7]; P = 0.0001), which was higher than the odds based on MR or PET alone. TNMRmax achieved an area under the receiver-operating characteristic curve of 0.90 for separating MR(+)PET(+)FOCAL from non-MR(+)PET(+)FOCAL, and 0.77 for separating those reaching the clinical endpoint from those not reaching the clinical endpoint | ||
| 520 | |a CONCLUSIONS: Hybrid MR/PET image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had modest sensitivity and specificity for quantifying the imaging-based classification MR(+)PET(+)FOCAL and was associated with outcomes. Use of combined MR and PET image-based classification may have use in prognostication and treatment management in CS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiac sarcoidosis | |
| 650 | 4 | |a hybrid imaging | |
| 650 | 4 | |a magnetic resonance/positron emission tomography | |
| 650 | 4 | |a nuclear cardiology | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Gadolinium |2 NLM | |
| 650 | 7 | |a AU0V1LM3JT |2 NLM | |
| 700 | 1 | |a Robson, Philip M |e verfasserin |4 aut | |
| 700 | 1 | |a Vergani, Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a LaRocca, Gina |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Daza, Angelica M |e verfasserin |4 aut | |
| 700 | 1 | |a Abgral, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Devesa, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Azoulay, Levi-Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Karakatsanis, Nicolas A |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Panagiota, Christia |e verfasserin |4 aut | |
| 700 | 1 | |a Palmisano, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a DePalo, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Helena L |e verfasserin |4 aut | |
| 700 | 1 | |a Rothstein, Joseph H |e verfasserin |4 aut | |
| 700 | 1 | |a Fayad, Rima A |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Fuster, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Narula, Jagat |e verfasserin |4 aut | |
| 700 | 1 | |a Dweck, Marc R |e verfasserin |4 aut | |
| 700 | 1 | |a Morgenthau, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobi, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Padilla, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacic, Jason C |e verfasserin |4 aut | |
| 700 | 1 | |a Fayad, Zahi A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Cardiovascular imaging |d 2008 |g 17(2024), 4 vom: 01. Apr., Seite 411-424 |w (DE-627)NLM186259573 |x 1876-7591 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:411-424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcmg.2023.11.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 4 |b 01 |c 04 |h 411-424 | ||